Schwab Charles Investment Management Inc. increased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 5.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 282,765 shares of the medical research company’s stock after purchasing an additional 15,562 shares during the quarter. Schwab Charles Investment Management Inc. owned 0.60% of Charles River Laboratories International worth $30,545,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CRL. Lord Abbett & CO. LLC acquired a new position in Charles River Laboratories International during the second quarter worth about $65,915,000. FMR LLC increased its stake in shares of Charles River Laboratories International by 23.8% in the second quarter. FMR LLC now owns 3,079,179 shares of the medical research company’s stock valued at $311,458,000 after buying an additional 591,066 shares during the period. TimesSquare Capital Management LLC acquired a new position in shares of Charles River Laboratories International in the third quarter valued at approximately $35,182,000. FIL Ltd increased its stake in shares of Charles River Laboratories International by 325.4% in the second quarter. FIL Ltd now owns 417,465 shares of the medical research company’s stock valued at $42,227,000 after buying an additional 319,324 shares during the period. Finally, Koch Industries Inc. acquired a new position in shares of Charles River Laboratories International in the second quarter valued at approximately $240,000. 96.27% of the stock is owned by institutional investors and hedge funds.

CRL has been the subject of several recent research reports. BidaskClub raised Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 22nd. Robert W. Baird reissued a “buy” rating and set a $114.00 target price on shares of Charles River Laboratories International in a research report on Friday, September 1st. Jefferies Group reissued a “buy” rating and set a $120.00 target price on shares of Charles River Laboratories International in a research report on Tuesday, September 12th. Royal Bank of Canada started coverage on shares of Charles River Laboratories International in a research report on Tuesday, September 19th. They set a “sector perform” rating and a $110.00 target price for the company. Finally, Credit Suisse Group reissued a “neutral” rating and set a $112.00 target price (up previously from $95.00) on shares of Charles River Laboratories International in a research report on Monday, October 16th. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $106.63.

In other Charles River Laboratories International news, Director C Richard Reese sold 10,227 shares of the stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $102.40, for a total transaction of $1,047,244.80. Following the transaction, the director now directly owns 51,444 shares in the company, valued at approximately $5,267,865.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Davide Molho sold 6,165 shares of the stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $110.00, for a total value of $678,150.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have acquired 10,500 shares of company stock worth $2,885 and have sold 1,016,392 shares worth $1,995,395. 2.20% of the stock is currently owned by corporate insiders.

Shares of Charles River Laboratories International, Inc. (CRL) opened at $103.90 on Tuesday. The firm has a market cap of $4,918.02, a P/E ratio of 20.40, a price-to-earnings-growth ratio of 1.66 and a beta of 0.89. Charles River Laboratories International, Inc. has a 52-week low of $73.13 and a 52-week high of $119.05. The company has a current ratio of 1.88, a quick ratio of 1.62 and a debt-to-equity ratio of 1.13.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. The firm had revenue of $464.23 million for the quarter, compared to analysts’ expectations of $458.93 million. Charles River Laboratories International had a return on equity of 26.58% and a net margin of 10.72%. The company’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.18 EPS. equities research analysts forecast that Charles River Laboratories International, Inc. will post 5.13 earnings per share for the current fiscal year.

WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/12/charles-river-laboratories-international-inc-crl-position-raised-by-schwab-charles-investment-management-inc.html.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.